Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: Survey on coverage rate among elderly and chronic patients

被引:14
|
作者
Martinelli, Domenico [1 ,2 ]
Tafuri, Silvio [2 ,3 ]
Caputi, Giovanni [2 ,3 ]
Fortunato, Francesca [2 ,3 ]
Reggio, Paolo [4 ]
Germinario, Cinzia [2 ,3 ]
Prato, Rosa [1 ,2 ]
机构
[1] Univ Foggia, Sez Igine, Dipartimento Sci Med & Lavoro, I-71000 Foggia, Italy
[2] Epidemiol Observ Puglia Reg, Bari, Italy
[3] Univ Bari, Sect Hyg, Dept Biomed Sci & Human Oncol, Bari, Italy
[4] Sanofi Pasteur MSD SpA, Rome, Italy
关键词
Pneumococcal 23-valent polysaccharide vaccine; invasive pneumococcal disease; vaccination coverage rate; COST-EFFECTIVENESS; OLDER-ADULTS; REVACCINATION; PNEUMONIA; DISEASE;
D O I
10.1016/j.ajic.2009.09.019
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Streptococcus pneumoniae, lancet-shaped, gram-positive, facultative anaerobic organisms, are common inhabitants of the respiratory tract and may be isolated from the nasopharynx of 5% to 70% of healthy adults. Objective: The aims of the study were to estimate the vaccination coverage for pneumococcal 23-valent polysaccharide vaccine and to assess the impact its introduction in the Italian region of Puglia, where a program to provide this vaccination has been operative since 2000. Methods: Estimation of the coverage for pneumococcal 23-valent polysaccharide vaccine was implemented by a 2-step study consisting of data collection from local health unit vaccination registers between 2000 and 2008 in Puglia and of a cluster sampling study among general practitioners to validate routine data collected during the first step. Moreover, hospitalization for invasive pneumococcal diseases was studied. Results: From 2000 to 2004, among individuals >= 65 years, the overall coverage rate estimated by routine data amounted to 26.3%; between 2005 and 2007, annual coverage rates did not exceed 8%/year. Between 2002 and 2007, the overall coverage rate estimated by interviewing general practitioners was 46.6% (95% confidence interval: 39.9-53.4). The coverage rate in chronic patients by routine data was approximately 23%, whereas the rate provided by general practitioners was 17.6% (95% confidence interval: 12.5-22.8). From 2001 to 2007, hospitalization data did not show a reduction in invasive pneumococcal disease trends among the elderly population in Puglia. Conclusion: The results of this study demonstrate the need for improving vaccine coverage and implementing new immunization strategies and practices.
引用
收藏
页码:E8 / E15
页数:8
相关论文
共 50 条
  • [31] 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events
    Ihara, Hiroaki
    Kikuchi, Kan
    Taniguchi, Hiromi
    Fujita, Shogo
    Tsuruta, Yuki
    Kato, Motoyasu
    Mitsuishi, Yoichiro
    Tajima, Ken
    Kodama, Yuzo
    Takahashi, Fumiyuki
    Takahashi, Kazuhisa
    Azuma, Nakanobu
    VACCINE, 2019, 37 (43) : 6447 - 6453
  • [32] Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study
    Kondo, Kyoko
    Suzuki, Kanzo
    Washio, Masakazu
    Ohfuji, Satoko
    Fukushima, Wakaba
    Maeda, Akiko
    Hirota, Yoshio
    VACCINE, 2017, 35 (36) : 4806 - 4810
  • [33] Safety of 23-Valent Pneumococcal Vaccine in Rheumatoid Arthritis Patients
    Naumtseva, Marina S.
    Belov, Boris S.
    Tarasova, Galina M.
    Karateev, Dmitriy E.
    Luchikina, Elena E.
    Muravyev, Yury V.
    Alexandrova, Elena N.
    Novikov, Alexander A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (04) : S21 - S21
  • [34] Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster
    Russell, F. M.
    Carapetis, J. R.
    Satzke, C.
    Tikoduadua, L.
    Waqatakirewa, L.
    Chandra, R.
    Seduadua, A.
    Oftadeh, S.
    Cheung, Y. B.
    Gilbert, G. L.
    Mulholland, E. K.
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (12) : 1970 - 1976
  • [35] Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan
    Hoshi, Shu-ling
    Kondo, Masahide
    Okubo, Ichiro
    PLOS ONE, 2015, 10 (10):
  • [36] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine
    Bryant, K. A.
    Frenck, R.
    Gurtman, A.
    Rubino, J.
    Treanor, J.
    Thompson, A.
    Jones, T. R.
    Sundaraiyer, V.
    Baxter, L. M.
    Gruber, W. C.
    Emini, E. A.
    Scott, D. A.
    Schmoele-Thoma, B.
    VACCINE, 2015, 33 (43) : 5854 - 5860
  • [37] Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case-control study of a single center
    Masuda, Toshihiro
    Nakatani, Eiji
    Shirai, Toshihiro
    Akamatsu, Taisuke
    Tamura, Kanami
    Takahashi, Shingo
    Tanaka, Yuko
    Watanabe, Hirofumi
    Endo, Yoshinari
    Suzuki, Takahito
    Saigusa, Mika
    Yamamoto, Akito
    Morita, Satoru
    Sato, Yoko
    Asada, Kazuhiro
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [38] Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age
    Greenberg, Richard N.
    Gurtman, Alejandra
    Frenck, Robert W.
    Strout, Cynthia
    Jansen, Kathrin U.
    Trammel, James
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2014, 32 (20) : 2364 - 2374
  • [39] A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly
    MacIntyre, C. Raina
    Ridda, Iman
    Gao, Zhanhai
    Moa, Aye M.
    McIntyre, Peter B.
    Sullivan, John S.
    Jones, Thomas R.
    Hayen, Andrew
    Lindley, Richard I.
    PLOS ONE, 2014, 9 (04):
  • [40] Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia
    Törling, J
    Hedlund, J
    Konradsen, HB
    Örtqvist, Å
    VACCINE, 2003, 22 (01) : 96 - 103